Causes and Diagnosis of Muscle Weakness

Broad Categories and Diagnostic Approach

The American Academy of Neurology and the American College of Rheumatology recommend a systematic evaluation to identify inflammatory versus noninflammatory causes of muscle weakness, with particular attention to life-threatening etiologies 1, 2, 3
Dermatomyositis presents with symmetric proximal muscle weakness developing over weeks to months, coupled with characteristic skin findings and elevated muscle enzymes, according to the European League Against Rheumatism 4
Polymyositis causes proximal muscle weakness without the skin manifestations of dermatomyositis, with inflammatory infiltrates on muscle biopsy, as stated by the American College of Rheumatology 1
Immune-mediated necrotizing myopathy presents with acute or subacute onset of severe proximal weakness, CK levels often exceeding 10 times normal, and minimal inflammatory infiltrate on biopsy, according to the American Academy of Neurology 4

Inclusion body myositis affects patients over 50 years with insidious onset of asymmetric weakness involving both proximal and distal muscles, particularly forearm flexors, finger flexors, and quadriceps, with dysphagia as a prominent feature, as described by the American Academy of Neurology 4
Muscular dystrophies, including late-onset limb-girdle dystrophy and dysferlinopathies, present with proximal weakness and elevated CK, according to the American Academy of Neurology 1, 2, 3
Mitochondrial myopathies demonstrate subsarcolemmal mitochondrial accumulation with "ragged red fibers" on Gomori trichrome stain and cytochrome c oxidase deficiency, as stated by the American College of Medical Genetics and Genomics 1, 2, 3

Creatine kinase is elevated in most inflammatory myopathies, muscular dystrophies, and some metabolic myopathies, approximately 95% of late-onset Pompe patients have elevated CK, though some adults may have normal levels, according to the American Association for Clinical Chemistry 4, 5
EMG confirms myopathic process and targets muscle for biopsy, as recommended by the American Academy of Neurology 1, 4, 2, 3
Muscle biopsy is the gold standard for confirming inflammatory myopathy diagnosis and differentiating inflammatory from noninflammatory causes, according to the American College of Rheumatology 1, 2, 3

Hypophosphatemia directly causes respiratory muscle weakness through cellular ATP depletion, particularly in patients receiving continuous renal replacement therapy, with a prevalence of 60-80%, as stated by the National Kidney Foundation 6
Severe hypokalemia causes respiratory muscle weakness affecting the diaphragm and accessory muscles, manifesting as reduced vital capacity and impaired cough, according to the American Heart Association 7
Thyroid disorders, both hypothyroidism and hyperthyroidism, cause proximal muscle weakness with normal or mildly elevated CK, as described by the American Thyroid Association 1, 2

Distinguishing true weakness from subjective fatigue requires objective grading using formal tools, true weakness is defined as loss of power resulting in reduced motor function, as recommended by the American Academy of Neurology 8, 9
Muscle weakness is more typical of myositis than pain, pain predominance suggests neuropathy or radiculopathy rather than primary muscle disease, according to the American College of Rheumatology 8, 9
Respiratory muscle involvement can rapidly progress to life-threatening failure, particularly with severe hypokalemia, hypophosphatemia, Guillain-Barré syndrome, myasthenia gravis, and immune checkpoint inhibitor myositis, as stated by the American Thoracic Society 6, 7

Measuring aldolase, AST, ALT, and LDH alongside CK provides additional diagnostic clues because these enzymes can be elevated even when CK is normal, helping to detect inflammatory or dystrophic myopathies. 10
Obtaining ESR and CRP assists in distinguishing inflammatory myositis (typically elevated) from steroid‑induced or endocrine myopathy (usually normal). 10
Troponin measurement together with ECG and echocardiography is mandatory, as cardiac involvement (myocarditis, cardiomyopathy, arrhythmias) is a major determinant of mortality in inflammatory myopathies and muscular dystrophies. 10

Testing for myositis‑specific autoantibodies (e.g., anti‑Jo‑1, anti‑Mi‑2, anti‑SRP, anti‑HMGCR, anti‑NXP2, anti‑TIF1γ) defines disease sub‑groups, predicts pulmonary and cardiac complications, and differentiates autoimmune inflammatory myopathy from immune‑mediated necrotizing myopathy. [11][10]
ANA screening helps identify underlying connective‑tissue diseases that may present with myositis. (Supported by cited literature.) 11

Electromyography with nerve‑conduction studies should be performed to confirm a myopathic pattern (short‑duration, low‑amplitude motor units with fibrillation potentials) and to exclude neurogenic disorders such as spinal muscular atrophy or peripheral neuropathy. 11
EMG findings guide selection of the optimal biopsy target by identifying involved muscles while avoiding those with end‑stage atrophy. 11

Muscle MRI (T1‑weighted, T2‑weighted, STIR) is recommended to detect inflammation, direct biopsy site selection, establish a baseline for monitoring therapy, and differentiate infectious myositis (ring‑enhancing abscesses) from inflammatory myopathy. 11
In pediatric patients with suspected juvenile dermatomyositis, MRI can often replace invasive EMG or biopsy when findings are straightforward. 11

Muscle biopsy remains the gold standard for confirming inflammatory myopathy and distinguishing it from non‑inflammatory causes such as muscular dystrophy (dystrophin loss, fiber degeneration, fatty replacement) or mitochondrial myopathy (ragged‑red fibers, cytochrome‑c oxidase deficiency). 11
The contralateral muscle to the one studied by EMG should be biopsied to avoid sampling artifact from needle trauma. 11
Selecting a weak muscle that shows EMG abnormalities but is not end‑stage atrophic maximizes diagnostic yield. 11

When biopsy reveals dystrophic features or a hereditary pattern is suspected, targeted genetic testing for the dystrophin gene and broader muscular‑dystrophy panels is indicated. 11
Detection of ragged‑red fibers or cytochrome‑c oxidase deficiency on biopsy warrants mitochondrial DNA analysis and nuclear gene panel testing. 11

Patients presenting with dermatomyositis‑type skin findings (heliotrope rash, Gottron papules, photosensitive erythema) or who test positive for anti‑TIF1γ or anti‑NXP2 antibodies should undergo age‑appropriate cancer screening, as these features are strongly associated with paraneoplastic myositis. [11][10]

Objective strength testing is essential to differentiate true muscle weakness (more typical of myositis) from subjective fatigue or pain, which may suggest neuropathic or radiculopathic processes. 10
Checkpoint‑inhibitor‑associated myositis carries an approximate 20 % mortality rate; immediate high‑dose corticosteroids and urgent cardiology evaluation are required because concurrent myocarditis markedly worsens prognosis. 10